Business headlines from the Apex backend, organized by sectors and major public companies for faster market scanning.
In a response published after news coverage of alleged policy violations in India, Meta said its systems had already disabled some ads before additional actions, and described how automated checks and manual reviews work across advertising accounts.
THE APEX TIMES
THE APEX TIMES
A fresh look at analyst sentiment in Amazon’s stock points to a “buy” leaning, but the framing also highlights a common investor dilemma: how much weight to put on optimistic ratings when the underlying track record and assumptions are unclear.
THE APEX TIMES
A new comparison of year-to-date results highlights how narrowly Coca-Cola’s stock has tracked the consumer-staples complex, underscoring how much stock moves are being driven by broad market rotation rather than fundamentals alone.
THE APEX TIMES
A fresh wave of coverage points to a favorable average brokerage recommendation for Costco, yet investors are debating whether analyst calls are a reliable guide. The discussion comes as the membership-driven retailer leans on new customer offers and partnerships to keep momentum.
THE APEX TIMES
A reported enterprise expansion with Mexico’s leading insurer arrives as Palantir shares have struggled, with the stock down sharply in June.
THE APEX TIMES
Micron shares fell after news that it has locked in a long-term supply arrangement with Ford, underscoring how quickly macro sentiment can overwhelm company-specific headlines in the memory-chip space.
THE APEX TIMES
Nvidia shares slid amid a market report that DeepSeek is developing a custom chip, raising questions about how much demand will shift away from Nvidia’s graphics-processing units and AI accelerators.
THE APEX TIMES
A drop in AI-related names and memory-chip weakness set the tone for an uneven session, with investors rotating between semiconductor exposure and higher-beta “next theme” stocks.
THE APEX TIMES
Ahead of SpaceX’s expected addition to the Nasdaq-100, analysts at Goldman Sachs and Morgan Stanley issued sharply divergent valuation views, with Goldman’s $205 target contrasting with Morgan Stanley’s $300.
